drug discovery and development

Agios is a biopharmaceutical company founded in 2008 in Cambridge, Massachusetts, focused on cellular metabolism and developing therapies for rare diseases, with a near-term focus on hemolytic and acquired anemias. Its first rare disease therapy was approved by the FDA for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, and it is developing mitapivat and AG-946.

cellular metabolism researchClinical trials

AN2 Therapeutics is a clinical-stage biopharmaceutical company using a boron-based discovery platform to discover and develop medicines for infectious diseases and cancer. Its pipeline includes programs in polycythemia vera, Chagas disease, M. abscessus, and oncology targets PI3K and ENPP1, with lead compound epetraborole. The company is headquartered in Menlo Park, California.

boron-based drug discovery platformclinical developmentmedicinal chemistry

Aquilus Pharmaceuticals is a Pre-series A biotech dedicated to developing a first-in-class medication for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). It has been funded via the ALS Association, NIH, and Department of Defense grants in developing a new therapeutic (AQU-118) to treat ALS. The company has completed IND enabling studies for AQU-118 and is on track toward a phase I trial in the first quarter of 2026.

Clinical trialsresearch and development

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases. It has developed a drug discovery and development platform that integrates medicinal chemistry and systems biology through machine learning to identify and develop novel drugs for patients with autoimmune and chronic inflammatory diseases.

computational medicinal chemistryMachine Learningmedicinal chemistrysmall molecule synthesissystems biology

Attana AB is a Swedish life science company that provides the life science community with analytical instruments and services for bioanalysis. Its proprietary biosensor technology measures molecular interactions in real time in biologically relevant environments such as blood, plasma, living cells and tissue, helping drug developers validate, select and optimize drug candidates for Phase I and Phase II studies. The company also offers contract research (CRO) services and diagnostics through Attana Diagnostics and Attana Virus Analytics (AVA).

antibody developmentbiosensor technologycell-based assaysimmunogenicity studiesinteraction analysiskinetic analysislabel-free analysistranslational researchvaccine development

Auni Therapeutics is a biotech company developing a next-generation immunotherapy for food allergies, with a platform designed to expand across multiple allergens and deliver durable clinical benefits. The company is led by a multidisciplinary executive team of physician-scientists, serial entrepreneurs, and operational leaders focused on translating next-generation immunology into therapeutic assets.

clinical strategyimmunotherapy developmenttranslational research

DermaXon is a Montana-based drug discovery and development company founded in 2013 providing first-in-class drug candidates. It targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization. Its core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology.

medicinal chemistrymolecular biologyRNA sequencingsmall molecule design and development

DIMERx, Inc. is a clinical-stage biopharmaceutical company developing first-in-class, covalently linked dimer-based therapeutics to address major public-health challenges in pain management and the opioid crisis. Its pipeline includes DMX-101 (buprenorphine dimer, Phase 2), DMX-201 (arginine-agmatine dimer, IND-enabling) and DMX-105 (acetaminophen dimer, IND-enabling). Development is supported by competitive NIH awards, including an $18M mandate.

clinical developmentcovalent dimerization technology platformmedicinal chemistrypreclinical developmentregulatory strategy

ENDACEA (RTP, NC) is a biopharmaceutical research and development company that has been at the forefront of biopharmaceutical R&D since 1996. Led by Constance Neely Wilson, M.D., the company outsources operations and develops innovations including a mutant plasmid cDNA for the A1 adenosine receptor as a treatment for cancer, and its lead compound A1 adenosine receptor antagonist, L-97-1, as an intravenous treatment for sepsis and acute renal failure.

biopharmaceutical research and developmentoutsourcing operationsvirtual R&D

Endure Biotherapeutics is leading the discovery, development, and commercialization of engineered, engraftable live biotherapeutics for the treatment of genetic and chronic diseases. Its platform engineers native bacterial strains that remain resident in the gastrointestinal tract, delivering therapeutic proteins missing or nonfunctional in diseased conditions. The bioengineered live biotherapeutics are cultured and administered as an oral capsule containing freeze-dried bacteria.

bacterial culturingfreeze-dryinggenetic engineering of native bacteriamolecular biology techniques

Estrigenix Therapeutics, Inc. was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women. It is a privately held pharmaceutical company working on a family of compounds to address menopause symptoms, moderating hot flashes and improving memory without the risks of breast cancer and stroke associated with traditional hormone replacement therapy, based on expertise in estrogen biology.

Clinical trialsestrogen biology researchmedicinal chemistrypharmacology

Eton Pharmaceuticals is an innovative pharmaceutical company that searches the world over for meaningful therapies to bring to patients living with rare diseases. It discovers and develops therapies for small patient populations, sourcing potential therapies worldwide and navigating the drug development and FDA approval process to bring promising therapies to market. The company has brought multiple approvals to market in just 4 years, with more in the pipeline.

Clinical trialscommercializationFDA approval navigationsourcing therapies worldwide